| Name | Title | Contact Details |
|---|---|---|
Nallakkan Arvindan |
Chief Technology Officer | Profile |
ParagonRx is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trimeris is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Part of UK-based Bio Products Laboratory, BPL Plasma has been a global leader in the plasma collection industry for more than 25 years. We`re proud to support the creation & manufacturing of lifesaving drug therapies by supplying high-quality plasma to people in need. At BPL Plasma, the people who walk into our centers are much more than donors — they are lifelines. Their donation, quite literally, transforms the lives of patients around the planet. Donating plasma makes it possible for: - An expectant mother to carry her child safely to term. - A little boy with hemophilia to experience a healthy, happy childhood. - A wounded warrior or burn victim to begin the healing process.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
OutcomesMTM is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.